The Wegovy pill, priced and read against its own trial
The first oral semaglutide approved for weight loss is real, cheap to start, and more expensive once you reach the treatment dose. Here is the whole picture, and what it does to compounded oral products.
The FDA approved Wegovy tablets (oral semaglutide 25 mg) on December 22, 2025 — the first oral GLP-1 approved for chronic weight management — and it launched January 5, 2026 at $149 per month self-pay for the 1.5 mg starting dose. In the OASIS 4 trial, participants averaged 13.6% weight loss at 64 weeks (16.6% among those who stayed on treatment). The catch is dose-tier pricing: the 9 mg and 25 mg maintenance doses run about $299 per month cash.
- What OASIS 4 showed: OASIS 4 was a 64-week randomized, double-blind, placebo-controlled trial in adults with obesity, or overweight plus a weight-related condition, exclud.
- Pill versus injection versus Rybelsus: The 16.6 percent adherent figure is broadly in line with injectable Wegovy 2.4 mg, which produced about 14.9 percent in STEP-1.
- The dose-tier pricing nobody headlines: The $149 launch price is for the 1.5 mg starting dose.
- What it does to compounded oral products: The Wegovy pill directly undercuts the marketing premise of compounded oral and sublingual semaglutide.
- Who the pill fits, and who it doesn't: The pill fits needle-averse patients, travelers who can't refrigerate pens, and anyone whose insurance copay lands near $25.
What OASIS 4 showed
OASIS 4 was a 64-week randomized, double-blind, placebo-controlled trial in adults with obesity, or overweight plus a weight-related condition, excluding people with diabetes. On the treatment-policy analysis — everyone randomized — oral semaglutide 25 mg produced 13.6 percent mean weight loss versus 2.4 percent with placebo. Among participants who adhered to treatment, the average was 16.6 percent.
Two secondary findings matter. About one-third of adherent participants lost at least 20 percent of body weight. And among those with prediabetes at baseline, a large majority returned to normal blood glucose. Serious adverse events were less frequent on semaglutide than placebo; the common side effects were the familiar GLP-1 trio of nausea, diarrhea, and vomiting.
| Dose | Role | Cash price/mo | Notes |
|---|---|---|---|
| 1.5 mg | Starting dose | $149 | Launch price; savings offers |
| 4 mg | Titration | $149–$199 | Promo windows |
| 9 mg | Titration | $299 | GoodRx / NovoCare |
| 25 mg | Treatment dose | $299 | OASIS 4 dose |
| Insured copay | Any covered dose | ~$25 | Savings program, eligibility required |
Pill versus injection versus Rybelsus
The 16.6 percent adherent figure is broadly in line with injectable Wegovy 2.4 mg, which produced about 14.9 percent in STEP-1. It sits below injectable tirzepatide, the class efficacy leader. So the pill is competitive with injectable semaglutide, not a leap beyond it.
It is also distinct from Rybelsus, the older oral semaglutide approved for type 2 diabetes at doses up to 14 mg. The Wegovy pill is a 25 mg formulation approved specifically for weight management. Both are swallowed tablets that share the empty-stomach, small-sip-of-water, 30-minute-wait protocol — the ritual that is the most common real-world adherence complaint with oral semaglutide.
The dose-tier pricing nobody headlines
The $149 launch price is for the 1.5 mg starting dose. The tablet comes in 1.5, 4, 9, and 25 mg strengths, and titration to the 25 mg treatment dose is the intended path — OASIS 4 escalated over about 12 weeks. Through GoodRx, starter doses were $149 and the 9 and 25 mg doses about $299 per month; Novo's savings offers can bring commercially insured copays as low as $25.
So a realistic self-pay year is not 12 × $149. A typical titration — a few months at starter tiers, the rest at 25 mg — lands roughly $2,900–$3,200 for year one before any clinic fees. That is comparable to injectable Wegovy's self-pay tiers and still above the lowest compounded semaglutide programs, with the difference that the pill is FDA-approved and trial-backed.
What it does to compounded oral products
The Wegovy pill directly undercuts the marketing premise of compounded oral and sublingual semaglutide. Those products — ODT tablets, sublingual drops — now compete against an FDA-approved oral semaglutide with published Phase III evidence at a $149 entry price. For any compounded oral product priced at or above that, the value proposition is hard to defend.
Compounded injectable semaglutide is a different calculation: the cheapest programs can still undercut the pill's maintenance-dose cost, which keeps that market alive for cash-pay patients — subject to the legality constraints covered in our compounding-rules guide. But the compounded oral segment specifically is the one the approved pill threatens most directly.
Who the pill fits, and who it doesn't
The pill fits needle-averse patients, travelers who can't refrigerate pens, and anyone whose insurance copay lands near $25. It fits less well if you struggle with a fasting-window routine, if you're chasing maximum weight loss and tolerate injections (where tirzepatide leads), or if you take morning medications whose timing conflicts with the 30-minute rule.
Switching is supported: Novo's labeling allows moving between the 25 mg tablet and the 2.4 mg weekly injection, and any switch — including from compounded semaglutide to the approved pill — should run through a prescriber, because dose equivalence between routes is not one-to-one. The pill's arrival mainly expands the menu of proven options rather than replacing injections.
The bottom line
For a patient weighing semaglutide options in 2026, the Wegovy pill adds a genuinely proven oral choice to a menu that previously forced a needle. Its trial results are solid, its entry price is low, and its maintenance price is moderate. Its main limitations are the fasting ritual and a maintenance cost above the compounded floor.
The strategic point for this site: the pill sits in the brand/approved tier of our pricing work, tracked against the compounded injectable floor. It does not make compounded semaglutide obsolete, but it removes the last easy argument for unproven compounded oral formulations — there is now a cheap, approved, trial-backed pill in that lane.
Frequently asked questions
Is the Wegovy pill the same as Rybelsus?
Same molecule, different product. Rybelsus is oral semaglutide approved for type 2 diabetes up to 14 mg; the Wegovy pill is a 25 mg formulation approved December 2025 for weight management, with its own OASIS trial evidence.
Does the $149 price last?
$149 is the launch price for the starter dose. Maintenance doses run about $299 cash, and promotional windows have end dates. Treat $149 as an entry price, not your steady-state cost.
Should I choose the pill over compounded semaglutide?
The pill is FDA-approved and trial-backed; the cheapest compounded injectable programs may still cost less per month. The pill most clearly outcompetes unproven compounded oral and sublingual products, which have no equivalent evidence.
Sources
- Novo Nordisk — Wegovy pill approval, Dec 22, 2025
- OASIS 4 publication (NEJM)
- Launch pricing (Fierce Pharma)
- STEP-1 injectable semaglutide (NEJM 2021)
The numbers behind this page
The semaglutide price range, stated precisely
Standard-dose compounded semaglutide runs $119 to $299 a month across the 12 programmes we can price, with a median of $198. The spread between cheapest and dearest is $166 a month, or $1,992 across a year, for a molecule that is chemically identical in every case.
The cheapest verified figure is NexLife at $119 on its 12-month plan; Oak Longevity follows at $133. Half the market sits below $198 and half above it, which makes the median a more useful reference point than the cheapest figure when judging whether a quote is reasonable.
2 programmes additionally advertise a semaglutide microdose, the cheapest at $145 a month. Those figures are excluded from the range above. A microdose sits below every dose studied in the pivotal trials, so including it would compare two different things and would make the market look cheaper than it is at a therapeutic dose.
Three structural facts move a bill more than the headline rate. Whether the price is flat across covered doses or rises as you titrate. Whether a membership is billed separately from medication. And whether the advertised figure requires prepaying six or twelve months, which lowers the monthly number by transferring risk to you at exactly the point you are least certain you will continue.
Three questions to ask before acting on semaglutide
The semaglutide figures on this page span $119 to $299 a month across 12 programmes.
Ask in writing, before enrolling anywhere. Is the quoted figure the month-to-month rate, or does it require a prepaid term? Does it include every mandatory recurring fee, or is a membership billed separately? And which pharmacy fills the prescription — a 503A compounding pharmacy or a 503B outsourcing facility, and is it licensed to ship to your state?
A programme answering all three plainly has given you what you need to verify it without us. One answering none has also told you something. Neither outcome requires trusting a comparison site.
Reading the price against the market
What a longer horizon costs
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
What a longer horizon costs
Standard-dose semaglutide spans $119 to $299 a month across 12 programmes we can price, a spread of $180.
At the cheapest verified semaglutide rate of $119 a month (NexLife, 12-month plan), medication alone runs $1,428 a year, $4,284 over three and $7,140 over five. At the dearest, $299 a month, the same horizons are $3,588, $10,764 and $17,940.
Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops. The relevant question is what a sustainable course costs, not what a first year costs.
A programme you can afford for five years is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome here, and price is only one of the reasons people discontinue — tolerability, supply interruption and administrative friction account for the rest.
Questions this page answers
What does compounded semaglutide normally cost?
$119 to $299 a month across 12 programmes, with a median of $198. Half the market sits either side of that median, which makes it a better reference than the cheapest figure when judging a quote.
Does compounded semaglutide cost more at higher doses?
At the programmes listed here the monthly price is flat across covered doses; what changes the figure is the plan term, not the dose. Dose-tiered pricing does exist elsewhere in this market, so confirm at checkout.
Why is microdosed semaglutide cheaper?
Because it is less medicine. 2 programmes advertise a semaglutide microdose, the cheapest at $145 a month. A microdose sits below every dose studied in the pivotal trials, so it is not a cheaper route to the result those trials measured.
What is the cheapest compounded semaglutide?
NexLife at $119 a month at a standard therapeutic dose on the 12-month plan ($1,428 total), captured 2026-09-04. 3-month $132; 6-month $125; month-to-month $139. No membership fee, flat at every covered dose. Verified. The next-cheapest is Oak Longevity at $133 (flat, no subscription; not available in California; Provider Reported).